Sotorasib, formerly AMG-510, was the first direct KRAS G12C inhibitor to enter clinical development (85), in a phase I/II first-in-human clinical trial (NSCLC cases in phase I=59 patients enrolled; NSCLC cases in phase II=126 patients enrolled; Table 1) (84, 85). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.